Vladimir Gubala

Ph.D.; Chemistry and Drug Delivery, Medway School of Pharmacy, University of Kent and Vital Signs Solutions, UK


Dr Vladimir Gubala obtained his B.Sc. and M.Sc. degrees in organic chemistry from the Slovak University of Technology, Bratislava, in 1999 and 2001 respectively. He then moved to the University of Puerto Rico, Rio Piedras, where in 2006 he received his Ph.D. in chemistry. His research focused on self-assembly of novel nanostructures and supramolecular chemistry. After a postdoctoral position at the University of Florida, he joined the research team at the Biomedical Diagnostics Institute (BDI) at Dublin City University (DCU) in 2007. He worked at BDI for nearly 5 years, managing a group of scientists working on novel surface chemistry approaches for the design of low cost diagnostics platforms. He started his appointment at the Medway School of Pharmacy in January 2012, where he developed his research, which now focuses on materials science, bio-organic and analytical chemistry and nanotechnology. His scientific interest in academia include the development of novel multimodal carriers for targeted drug delivery based on silica nanoparticles and the development of novel, implantable material for the treatment aggressive brain cancer. In 2015, he co-founded a diagnostics company called Vital signs Solutions Ltd. He employs a small group of scientist working on the next generation of point-of-care test to monitor and detect series of biomarkers, which is aimed to empower people to make informed choices about their lifestyle and prevent many conditions and diseases. In 2020, the company has developed a new, antibody-based Covid-19 finger prick test in collaboration with Biosure, The test is currently in clinical trials testing and it will be available on the market in early 2021. Vladimir has been a member of IUPAC since 2011, he is currently a secretary of Division VII – Chemistry and Human Health and a Chair of
Interdivisional Subcommittee of Materials Chemistry ISMC).